Sign in

You're signed outSign in or to get full access.

Adi Jayaraman

Research Analyst at Evercore ISI

Adi Jayaraman is a Partner and Senior Managing Director in Evercore’s Technology group, specializing in advising clients on M&A and capital markets transactions in the fintech and information services sectors globally. With nearly two decades of experience, he has executed deals representing over $100 billion in announced value across high-growth fintech, digital finance, financial software, market structure, payments, and financial data areas, though specific performance metrics like success rates or rankings are not publicly detailed. Jayaraman joined Evercore from Citi where he served as a Managing Director in the fintech and information services investment banking division, following roles at J.P. Morgan and starting his career at Morgan Stanley. He holds an MBA from the Wharton School at the University of Pennsylvania, an M.S. in computer science from Baruch College, CUNY, and a B.A. in economics from the University of Delhi.

Adi Jayaraman's questions to BridgeBio Pharma (BBIO) leadership

Question · Q4 2025

Adi Jayaraman, on behalf of Cory Kasimov, asked about BridgeBio's perspective on the competitive landscape for infigratinib in achondroplasia, following the Phase III data, specifically against CNP pathway therapies and other FGFR3-targeted programs.

Answer

Justin To, CEO of Skeletal Dysplasias, asserted that infigratinib's balance of efficacy (+2.1 cm/year, first and only statistically significant proportionality improvement, normalized HV) and safety (no change in phosphate, no FGFR1/2 toxicity) positions it as best-in-class. He highlighted the known issues with CNP class therapies (vasodilation) and other FGFR3 inhibitors (VEGFR3 liabilities, spermatogenesis, impaired wound healing) as competitive disadvantages.

Ask follow-up questions

Fintool

Fintool can predict BridgeBio Pharma logo BBIO's earnings beat/miss a week before the call

Question · Q4 2025

Adi Jayaraman, on behalf of Cory Kasimov, asked about BridgeBio's perspective on the competitive landscape for infigratinib in achondroplasia, considering both CNP pathway therapies and other FGFR-targeted programs more specific to FGFR3, following the Phase 3 data.

Answer

Justin To, CEO of Skeletal Dysplasias at BridgeBio, stated that infigratinib's balance of efficacy (+2.1 cm/year change, first statistically significant proportionality improvement, normalized absolute HV) and safety (no change in mean phosphate, no FGFR1/2 toxicity) makes it best-in-class and potentially last-in-class. He highlighted that other molecules (CNP or FGFR3 inhibitors) have issues with overshooting growth or VEGFR3 liabilities (spermatogenesis, impaired wound healing), which infigratinib avoids.

Ask follow-up questions

Fintool

Fintool can write a report on BridgeBio Pharma logo BBIO's next earnings in your company's style and formatting